Evidence map›Paper›PMID 38967649›Full record

ArticleCancer immunology, immunotherapy : CII2024

Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.

Katharina Seel, Ronja Larissa Schirrmann, Daniel Stowitschek, Tamar Ioseliani, Lea Roiter, Alina Knierim, Maya C André

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katharina SeelDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Ronja Larissa SchirrmannDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Daniel StowitschekDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Tamar IoselianiDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Lea RoiterDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Alina KnierimDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany.
Maya C AndréDepartment of Pediatric Hematology and Oncology, University Children´s Hospital, Eberhard Karls University, Hoppe-Seyler-Str.1, 72076, Tuebingen, Germany. maya.andre@med.uni-tuebingen.de.

Funding

Deutsche Krebshilfe, Germany No. 70114413Faculty of Medicine of Tuebingen No. 2019-1-14, No. 2023-01-01, No. 2021-01-15
6 · The paper itself

Abstract

TIGIT is an alternative checkpoint receptor (CR) whose inhibition promotes Graft-versus-Leukemia effects of NK cells. Given the significant immune-permissiveness of NK cells circulating in acute myeloid leukemia (AML) patients, we asked whether adoptive transfer of activated NK cells would benefit from additional TIGIT-blockade. Hence, we characterized cytokine-induced memory-like (CIML)-NK cells and NK cell lines for the expression of inhibitory CRs. In addition, we analyzed the transcription of CR ligands in AML patients (CCLE and Beat AML 2.0 cohort) in silico and evaluated the efficacy of CR blockade using in vitro cytotoxicity assays, CD69, CD107a and IFN-γ expression. Alternative but not classical CRs were abundantly expressed on healthy donor NK cells and even further upregulated on CIML-NK cells. In line with our finding that CD155, one important TIGIT-ligand, is reliably expressed on AMLs, we show improved killing of CD155

Indexed as

Immunologic MemoryKiller Cells, NaturalLeukemia, Myeloid, AcuteReceptors, ImmunologicReceptors, VirusCytokinesFemaleHumansMaleCytokinespoliovirus receptorReceptors, ImmunologicReceptors, VirusTIGIT protein, humanAcute myeloid leukemiaCheckpoint receptor inhibitionNatural killer cellsNK-92 cell lineTIGIT

Identifiers

PMID38967649
PMCPMC11226419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.